CV Sciences, Inc. Experts Contribute to Journal of Dietary Supplements First Special Issue on Cannabinoids

SAN DIEGO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- CV Sciences, Inc. (OTCQB:CVSI) (the “Company”, “CV Sciences”, “our”, “us” or “we”), a preeminent leader in hemp-derived cannabidiol (CBD) products, is pleased to announce the publication of two papers in the Journal of Dietary Supplements’ first Special Issue on Cannabinoids. 

In this issue, CV Sciences’ team of physicians and scientists took the opportunity to contribute to the growing body of scientific evidence on hemp-derived CBD as a non-prescription product.

Dr. Douglas Mackay, N.D., Senior Vice President of Scientific and Regulatory Affairs for CV Sciences teamed up with Cannabis expert and academic Dr. Igor Koturbash, M.D., Ph.D., Associate Professor and Vice Chair of Environmental and Occupational Health at the Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences as co-editors of the Special Issue on Cannabinoids and provided the editorial, “Cannabidiol and Other Cannabinoids: From Toxicology and Pharmacology to the Development of a Regulatory Pathway." The editorial outlines the intent of the Special Issue on Cannabinoids, which is to address key scientific questions related to benefits, safety, and composition of popular hemp-derived CBD products.

Dr. Osvaldo Marinotti, Ph.D., Senior Scientist, CV Sciences, and Miles Sarill, M.Sc., National Educator for CV Sciences, co-authored, “Differentiating Full-Spectrum Hemp Extracts from CBD Isolates: Implications for Policy, Safety and Science.”

Both papers intended to add peer-reviewed scientific evidence that supports FDA’s request for “data that may help to address uncertainties and data gaps related to CBD, including real world evidence to address safety questions”.

Joseph Dowling, CV Sciences Chief Executive Officer, stated, “Observations from the food, supplement and cosmetic industries suggest that consumers expect a responsible, transparent, and science backed industry, that is fully FDA regulated. We agree with consumers, and that’s why we continue to lead the industry in advancing CBD science and regulatory compliance. We are proud to contribute our team’s expertise to this important cannabinoid report in the Journal of Dietary Supplements. These efforts help develop a framework for an FDA regulated industry that consumers can trust.”